Ibalizumab: First Global Approval

TaiMed Biologics is developing ibalizumab (Trogarzo™, ibalizumab-uiyk)—a humanised IgG4 monoclonal antibody—as a treatment for HIV-1 infection. Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunological function and is the first CD4-directed post-attachment HIV-1 inhibitor and...

Descripción completa

Detalles Bibliográficos
Autor principal: Markham, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988774/
https://www.ncbi.nlm.nih.gov/pubmed/29675744
http://dx.doi.org/10.1007/s40265-018-0907-5
_version_ 1783329345590263808
author Markham, Anthony
author_facet Markham, Anthony
author_sort Markham, Anthony
collection PubMed
description TaiMed Biologics is developing ibalizumab (Trogarzo™, ibalizumab-uiyk)—a humanised IgG4 monoclonal antibody—as a treatment for HIV-1 infection. Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunological function and is the first CD4-directed post-attachment HIV-1 inhibitor and the first humanised monoclonal antibody for the treatment of HIV/AIDS. This article summarizes the milestones in the development of ibalizumab leading to this first approval in HIV-1 treatment.
format Online
Article
Text
id pubmed-5988774
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-59887742018-06-12 Ibalizumab: First Global Approval Markham, Anthony Drugs AdisInsight Report TaiMed Biologics is developing ibalizumab (Trogarzo™, ibalizumab-uiyk)—a humanised IgG4 monoclonal antibody—as a treatment for HIV-1 infection. Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunological function and is the first CD4-directed post-attachment HIV-1 inhibitor and the first humanised monoclonal antibody for the treatment of HIV/AIDS. This article summarizes the milestones in the development of ibalizumab leading to this first approval in HIV-1 treatment. Springer International Publishing 2018-04-19 2018 /pmc/articles/PMC5988774/ /pubmed/29675744 http://dx.doi.org/10.1007/s40265-018-0907-5 Text en © Springer Nature 2018, corrected publication May/2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
spellingShingle AdisInsight Report
Markham, Anthony
Ibalizumab: First Global Approval
title Ibalizumab: First Global Approval
title_full Ibalizumab: First Global Approval
title_fullStr Ibalizumab: First Global Approval
title_full_unstemmed Ibalizumab: First Global Approval
title_short Ibalizumab: First Global Approval
title_sort ibalizumab: first global approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988774/
https://www.ncbi.nlm.nih.gov/pubmed/29675744
http://dx.doi.org/10.1007/s40265-018-0907-5
work_keys_str_mv AT markhamanthony ibalizumabfirstglobalapproval

Ejemplares similares